Adagio Therapeutics Provides Update For ADG20 COVID-19 Antibody Program And Reports Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov 16 (Bernama-GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided an update on its lead COVID-19 antibody program, ADG20, and reported third quarter 2021 financial results. ADG20 is an investigational monoclonal antibody product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19.

http://mrem.bernama.com/viewsm.php?idm=41591